Accessibility Menu
Biotron logo

Biotron(OTC) BITRF

Current Price$0.00
Market Cap$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-99%
5 Year-94%
1 Year-79%
1 Month-60%
Biotron last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-15
Biotron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+81.82%USD 0.002026-05-22
1 month-60%USD 0.012026-05-07
3 month-93.78%USD 0.032026-02-17
Year to date-82.34%USD 0.012025-12-31
1 year-78.95%USD 0.012025-05-16
3 year-90.22%USD 0.022023-06-08
5 year-94.44%USD 0.042021-06-14
Since inception-98.57%USD 0.142013-03-25

Biotron Financials at a Glance

Market Cap

$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.81M

Net Income (TTM)

-A$3.35M

EPS (TTM)

-$0.00

P/E Ratio

-1.82

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$0.00

Volume

300,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Feb 26, 2026

BITRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotron

Biotron Limited is an Australian biotechnology firm dedicated to developing small-molecule compounds aimed at combating various viral infections. The company's lead antiviral agent, BIT225, is currently in Phase II clinical trials targeting SARS-CoV-2, HIV-1, and hepatitis C virus infections.

Products and Services
  • BIT225, an antiviral agent in clinical trials
  • Research and development of small-molecule compounds
  • Focus on viral infection treatments
Growth Outlook
  • BIT225 shows promise in treating multiple viral infections
  • Ongoing Phase II trials may lead to significant market opportunities
  • Potential partnerships could enhance research capabilities and funding
Financial Highlights
  • Recent quarterly revenue of AUD 1,644,114, indicating growth potential
  • Cash and cash equivalents of AUD 1,642,152, providing operational stability
  • Operating income of AUD -892,594, reflecting ongoing investment in R&D
Biotron Limited is positioned in the biotechnology sector, focusing on innovative antiviral treatments. The ongoing clinical trials for BIT225 could open new avenues for revenue generation, especially if successful. The company has maintained a solid cash position, which is crucial for funding its research and development efforts. Despite reporting operating losses, the strategic focus on viral infections aligns with growing global health needs, potentially attracting investor interest and partnerships. The company's commitment to advancing its clinical trials may lead to significant advancements in treatment options for viral infections, making it a noteworthy entity in the biotechnology landscape.
AI Generated • Jul 20, 2026

Industry

Biotechnology

CEO

Michelle Miller, PhD

Headquarters

Sydney, NSW 2000, AU

BITRF Financials

Key Financial Metrics (TTM)

Gross Margin

190.21%

Operating Margin

222203.69%

Net Income Margin

223061.06%

Return on Equity

-119.12%

Return on Capital

-61.38%

Return on Assets

-50.16%

Earnings Yield

-54.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.79B

Volume

300.00K

Avg. Volume

14.54K

Financials (TTM)

Gross Profit

A$1.78M

Operating Income

-A$3.37M

EBITDA

-A$3.35M

Operating Cash Flow

-A$1.74M

Capital Expenditure

-A$3.07K

Free Cash Flow

-A$1.74M

Cash & ST Invst.

A$1.64M

Total Debt

A$0.00

Biotron Performance Analysis

Biotron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Biotron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-100.0%
Q22024-12-30N/A
Q42025-06-30-100.0%
Q22025-12-31100.0%
Biotron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.004.2%
20242024-06-30AUD -0.00-12.0%
20252025-06-30AUD -0.00-90.9%
Biotron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-71.4%
Q22024-12-30125.0%
Q42025-06-30-266.7%
Q22025-12-31160.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$782.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$5.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.86M

N/A

Employees

3

N/A

Net Income

-A$920.61K

+30.5%

EBITDA

-A$891.81K

+34.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.64M

+127.5%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$0.00

N/A

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

-100.0%

Return on Assets

-50.16%

N/A

Return on Invested Capital

-71.46%

N/A

Free Cash Flow

-A$868.08K

+73.4%

Operating Cash Flow

-A$868.08K

+73.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GRCUGlobal Roundtable Corporation
$0.00+0.00%
TSOITherapeutic Solutions International, Inc.
$0.00+0.00%
DYNTDynatronics Corporation
$0.04+0.00%
VIRXViracta Therapeutics, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About BITRF

What is the current price of Biotron?

Biotron is trading at $0.00 per share.

What is the 52-week range for Biotron?

Over the past 52 weeks, Biotron has traded between $0.00 and $0.10.

How much debt does Biotron have?

As of the most recent reporting period, Biotron reported total debt of A$0.00.

How much cash does Biotron have on hand?

Biotron reported A$610.57K in cash and cash equivalents in its most recent financial results.

What is Biotron’s dividend yield?

Biotron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.